Physician profile
Charles E Rose
NPI 1568595874
$67,766.71
in general payments reported to CMS, 2019-2025
26 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $427 · 2021: $988 · 2022: $9,055 · 2023: $17K · 2024: $12K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Honoraria: $12K · Food and Beverage: $11K · Travel and Lodging: $4,458 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,075.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,375.00 |
| Honoraria | $11,985.00 |
| Food and Beverage | $11,135.86 |
| Travel and Lodging | $4,458.01 |
| Education | $247.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $22,056.64 | 2021-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $17,936.23 | 2022-2025 | Xerava, Xacduro, Zevtera |
| Viiv Healthcare Company | $16,927.61 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $2,992.90 | 2019-2025 | Biktarvy, Yeztugo, Veklury |
| Astrazeneca Uk Limited | $1,428.42 | 2023 | |
| Insmed, INC. | $1,327.26 | 2019-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $1,217.34 | 2019-2025 | Cresemba |
| Merck Sharp & Dohme LLC | $1,093.40 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $779.12 | 2019-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $703.40 | 2021-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Aimmune Therapeutics, INC. | $299.46 | 2023-2025 | Vowst |
| Tetraphase Pharmaceuticals, INC. | $261.88 | 2019-2025 | |
| Abbvie INC. | $150.37 | 2019-2025 | Dalvance |
| Pfizer INC. | $105.91 | 2022-2024 | |
| Theratechnologies INC. | $80.67 | 2019-2024 | Egrifta Sv |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $80.61 | 2024-2025 | Rebyota |
| Mayne Pharma Commercial LLC | $72.26 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $66.49 | 2024-2025 | Vibativ |
| Janssen Biotech, INC. | $47.15 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2022 | |
| Invivyd INC | $26.63 | 2024 | Pemgarda |
| Romark Laboratories, Lc | $20.56 | 2020 | |
| Vyera Pharmaceuticals, LLC | $17.47 | 2022 | |
| Shire North American Group INC | $17.25 | 2019 | |
| Angiodynamics, INC. | $16.46 | 2023 | Angiovac |
| Allergan, INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.